Viridian Therapeutics, Inc./DE Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Viridian Therapeutics, Inc./DE (VRDN) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $108.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-26
- Viridian Therapeutics, Inc./DE valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $108.30M, a 105.11% increase from fiscal 2024.
- Viridian Therapeutics, Inc./DE valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $52.80M, a 23.59% decline from fiscal 2023.
- Viridian Therapeutics, Inc./DE valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $69.10M, a 108.13% increase from fiscal 2022.
- Viridian Therapeutics, Inc./DE valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $33.20M, a 36.07% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $108.30M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $52.80M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $69.10M 10-K · filed 2026-02-26 | |
| 2022-12-31 | $33.20M 10-K · filed 2025-03-03 | |
| 2021-12-31 | $24.40M 10-K · filed 2024-02-27 | |
| 2020-12-31 | $17.20M 10-K · filed 2022-03-11 | -$17.20M 10-K · filed 2021-03-26 |
| 2019-12-31 | $13.10M 10-K · filed 2021-03-26 | |
| 2018-12-31 | $10.60M 10-K · filed 2020-03-13 | |
| 2017-12-31 | -$3.80M 10-K · filed 2019-03-14 | |
| 2016-12-31 | $7.40M 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |